[Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases]. (Record no. 25844957)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 01545 a2200397 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250517084943.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201701s 0 0 fre d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1773-0597 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1016/j.jfo.2015.10.009 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Maringe, E |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20170130 |
245 00 - TITLE STATEMENT | |
Title | [Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases]. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Journal francais d'ophtalmologie |
Date of publication, distribution, etc. | Mar 2016 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 255-60 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article; Observational Study |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Substitution |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Follow-Up Studies |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | France |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Intravitreal Injections |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Macular Degeneration |
General subdivision | complications |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Ranibizumab |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Receptors, Vascular Endothelial Growth Factor |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Recombinant Fusion Proteins |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Retinal Neovascularization |
General subdivision | complications |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Retrospective Studies |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Treatment Outcome |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Visual Acuity |
General subdivision | drug effects |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Letesson, E |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Duncombe, A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Muraine, M |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Genevois, O |
773 0# - HOST ITEM ENTRY | |
Title | Journal francais d'ophtalmologie |
Related parts | vol. 39 |
-- | no. 3 |
-- | p. 255-60 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1016/j.jfo.2015.10.009">https://doi.org/10.1016/j.jfo.2015.10.009</a> |
Public note | Available from publisher's website |
No items available.